J&J slips despite cheery 2026 guidance
Johnson & Johnson reported fourth-quarter sales that beat expectations and gave rosy guidance for 2026.
The company said it expects to bring in between $100 billion and $101 billion in revenue this year, compared to the $98.9 billion analysts polled by FactSet were expecting. The drugmaker also expects to report between $11.43 and $11.63 in annual adjusted earnings per share, compared to the $11.48 that Wall Street was expecting.
Despite beating expectations, J&J, the first major drugmaker to report earnings results this year, fell by more than 2% in premarket trading.
Analysts at Deutsche Bank pointed out that Q4 sales for two of J&J's newer and more lucrative drugs, Imbruvica and Carvykti, came in lower than expectations. Still, J&J’s overall numbers for the final three months of 2025 beat estimates.
It reported $24.6 billion in sales, compared to the $24.1 billion the Street was penciling in. It also reported adjusted earnings per share of $2.46, in line with expectations.
Analysts at Deutsche Bank pointed out that Q4 sales for two of J&J's newer and more lucrative drugs, Imbruvica and Carvykti, came in lower than expectations. Still, J&J’s overall numbers for the final three months of 2025 beat estimates.
It reported $24.6 billion in sales, compared to the $24.1 billion the Street was penciling in. It also reported adjusted earnings per share of $2.46, in line with expectations.